CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 50 enrolled
Drug / intervention
Adalimumabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01644396
NCT01644396Phase 4Completed
CompareCT.gov

An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab (Humira®) in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation

AbbVie (prior sponsor, Abbott)·interventional·Posted Jul 19, 2012·Updated Oct 1, 2014

In Brief

A Phase 4 clinical trial evaluating Adalimumab for Moderate to Severe Plaque Psoriasis. Completed, enrolled 50 participants across 7 sites.

Detailed Summary

This is an open-label study designed to establish the safety and effectiveness of adalimumab in the treatment of moderate to severe plaque psoriasis after 24 weeks of treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsModerate to Severe Plaque Psoriasis
CountriesRussia
Collaborators--

Timeline

Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJul 19, 2012
Enrollment StartMay 1, 2012
Primary CompletionSep 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 14.0 years ago

Interventions

Adalimumabbiological